BRIEF—ReiThera opens new viral vector facility in Italy

Italian contract development and manufacturing organization (CDMO) ReiThera is set to open a new viral vector production area at its facility in Italy.

The site enables large-scale GMP-compliant production of viral vectors for vaccines and gene therapies, based on adenovirus, adeno-associated virus (AAV) and lentivirus platforms.

ReiThera is seeking to meet growing global demand for viral vectors from small biotech companies to large multinational pharma groups.

The firm has already developed genetic vaccines against major infectious diseases, including hepatitis C, malaria, HIV, respiratory syncytial virus (RSV), Ebola and COVID-19.

The construction of the new production facility began in May 2020 with investment of around 15 million euros ($14.6 million).